Novo Nordisk links with Kallyope to tackle obesity, diabetes

Novo Nordisk (NOV: N) has announced a collaboration with Kallyope, a privately-held New York biotechnology platform developer, with the aim of developing novel therapies for diabetes and obesity.

The focus of their efforts will be the potential applications of peptides in the 'gut-brain axis', the system of biochemical signalling between the gastrointestinal tract and the central nervous system.

The deal will allow the Danish diabetes specialist to use Kallyope's unique development platform to target the gut-brain axis with novel biologics. Kallyope is set to contribute to the discovery process, though Nordisk will be solely responsible for any further drug development.